ViiV Healthcare

NEW YORK (GenomeWeb) — An Italian research group has developed a direct PCR-based approach for more simple and accessible pharmacogenomic testing to determine whether HIV patients carry the HLA-B*5701 marker associated with risk of serious side effects to the antiretroviral drug abacavir.

By Tony Fong
NEW YORK (GenomeWeb News) – As companion diagnostics gain acceptance within the pharmaceutical sector and next-generation sequencing progresses toward clinical applications, Siemens is seeking a bigger role in the genomics space.

Siemens Inks New Companion Dx Collaborations with ViiV Healthcare, Tocagen

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Siemens Healthcare Diagnostics today announced two deals to develop companion diagnostics for candidate drugs currently in clinical trials.

Lab21 will offer the service from its UK operations "with immediate effect," and eventually plans to offer the test as part of its comprehensive HIV service at its US facility in Greenville, SC.

A changing R&D paradigm fueled by the growing demand for personalized medicine is "one of the reasons that the pharmaceutical industry is facing rising taxes," a PricewaterhouseCoopers expert said. As a result, a PwC report released earlier this month advised pharma, biotech, and device firms to invest in tax planning early in their business strategic decisions.

According to ViiV CEO Dominique Limet, the new company’s unique structure has the potential to “re-energize” the pharmaceutical industry’s involvement in driving HIV treatment innovation and improving access.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.